louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04814641: Hypophosphatemia and Bronchiolitis
Official title: Hypophosphatemia In Infants With Severe Bronchiolitis: Prevalence And Risk Factors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypophosphatemia
Bronchiolitis
Keywords: Hypophosphatemia
Bronchiolitis
Paediatric Intensive Care Unit
Risk Factor
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2021-03-24
Enrollment: 400
Sex: ALL
Minimum age (years): 7
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit

Brief summary: Bronchiolitis is a major public health problem and the leading cause of paediatric intensive care unit admission in infants. Hypophosphatemia is common in adult intensive care units and was associated with an increase of the duration of mechanical ventilation and the length of stay. Our hypothesis is that hypophosphatemia is common in bronchiolitis and could be a marker of severity.


Eligibility criteria: Inclusion Criteria:

* Age \> 7 days and \< 3 months of life
* Admission to the pediatric intensive care unit from 01/11/2016 to 31/03/2020
* With a diagnosis of moderate to severe bronchiolitis according to HAS 2019 criteria

Exclusion Criteria:

* Renal Failure and tubulopathy
* Previous disorder of phospho-calcium balance
* Malignant pathology
* Lenght of stay less than 24 hours
* History of cardiac, aortic or hepatic surgery

Primary outcomes:
measure: hypophosphatemia occurrence in severe bronchiolitis in infants admitted in a pediatric intensive care unit
timeFrame: At any time in the first 5th days after Pediatric intensive care admission
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: Hopital Femme Mere Enfant - Groupement Hospitalier Est
Study officials:
References:
Clinical trial NCT05281419: Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery
Official title: Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery in Treating Refractory Granulomatous Lobular Mastitis: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Refractory Granulomatous Lobular Mastitis
Keywords: Granulomatous lobular mastitis
Corticosteroids
Surgery
Lead sponsor: Wuhan University
Sponsor class: OTHER
First posted: 2022-03-16
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Granulomatous lobular mastitis (GLM) is a rare, chronic benign inflammatory disease of the breast, of unknown etiology. Pathologically, GLM typically manifests as non-caseating granulomatous lesions with leukomonocytes, lymphocytes, neutrophils and multinucleated giant cells, located in the center of breast lobules. With a rapidly increasing morbidity in the last two decades, GLM tends to occur in child-bearing women with a prolonged and recurrent course. Intralesional injection and topical corticosteroids can effectively reduce the side effects, especially in patients suffering from concomitant skin lesions (e.g., fistula, skin erosions, ulcers).For patients with diffuse disease, recurrence, or ineffective conservative treatment, wide local excision can be applied.


Eligibility criteria: Inclusion Criteria:

* Patients who were pathologically diagnosed as refractory granulomatous lobular mastitis.
* Lesions are extensively distributed to more than three quadrants or with abscesses, sinus, fistula and persistent wound infection (skin ulceration and pus).
* Patients voluntarily participate in studies with informed consent.

Exclusion Criteria:

* History of breast surgery.
* Patients who choose conservative treatment.

Primary outcomes:
measure: Recovery rate
timeFrame: Up to two years
measure: Recurrence rate
timeFrame: Up to one year
Secondary outcomes:
measure: Scores of breast shape and cosmetic effect after surgery
timeFrame: Up to six months
measure: Degree of satisfaction
timeFrame: Up to one year
measure: Healing of incision
timeFrame: Up to six months
measure: Complications of surgical incision
timeFrame: Up to one year
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Qianqian Yuan
state: Hubei
Study officials:
References:
Clinical trial NCT06923319: Learning Curves of Different Devices for Vaginal Birth on Mannequin
Official title: Learning Curves for Odòn, Kiwi Vacuum, and Simpson Forceps for Vaginal Birth on Mannequin
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Forceps Delivery Affecting Fetus or Newborn
Ventouse Extraction;Liveborn
Birth; Forced
Keywords: Odòn
Kiwi vacuum
Simpson forceps
Lead sponsor: G. d'Annunzio University
Sponsor class: OTHER
First posted: 2025-04-11
Enrollment: 30
Sex: ALL
Minimum age (years): 24
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ObGyn specialists and residents involved on Labor ward in Pescara Hospital (above 2000 deliveries per year)

Brief summary: Learning curves for residents and specialists for devices applied on operative vaginal birth on mannequin (Odòn, Kiwi, Simpson forceps)

Detailed description: Residents and specialists were exposed to formal lecture having the opportunity of digital evaluation of digital support. After a frontal lecture they will have a formal explanation of mannequin approach for each device (Odòn, Kiwi, Simpson) After one month and after two month they will re-train on mannequin for each device.

Before frontal lecture they will answer to a questionnaire evaluating status of residency (year), elderly of specialization (years after degree) and personal experience in labor ward and on mannequin for training. After each training session they will have a further questionnaire evaluating how the training was working on their knowledge and on retaining of skills.

All training sessions will be recorded in a blind way erasing voice and face and with a ID computer generated code.

All videos will be evaluated by three different specialists of known experience on the three devices

Eligibility criteria: Inclusion Criteria:

* residents
* specialists

Exclusion Criteria:

* none

Primary outcomes:
measure: Learning curve
timeFrame: time 0
measure: retaining of skills
timeFrame: time 1 month
measure: retaining of skills
timeFrame: time 2 months
Secondary outcomes:
measure: physician approach
timeFrame: time 0, 1 onth and 2 months
measure: residency and year of specialist approach
timeFrame: time 0, 1 month, and 2 months
Other outcomes:
Locations:
city: Chieti
country: Italy
facility: University of Chieti
state: CH
city: Pescara
country: Italy
facility: Santo Spirito Hospital
state: PE
Study officials:
References:
Clinical trial NCT06727019: Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention
Official title: Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2024-12-10
Enrollment: 138
Sex: ALL
Minimum age (years): 7
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To compare the preventive effects of daily low-level red-light and 0.01% low-dose atropine eye drops on myopia.


Eligibility criteria: Inclusion Criteria:

* 1. Aged at least 7 years old. 2. The spherical equivalent error (SER) after pupil dilation was between -0.5 D and +0.75D.

  3. Had a record of cycloplegia SER at least 6 months before this study, and SER changed -0.5D compared with the last measurement or had a family history of high myopia.

  4. Corneal astigmatism ≤ 1.25D. 5. Interocular refraction discrepancy ≤ 1.5D. 6. No allergy history of cycloplegia drugs. 7. Willingness to participate in the study and signed informed consent.

Exclusion Criteria:

- 1. Intraocular pressure was below 10 mm Hg or higher than 22 mm Hg. 2. Presence of amblyopia, or ocular pathological conditions such as retinal, lens, or corneal disorders.

3. Children currently using other myopia interventions other than LDA or LLRL. 4. Children with systemic and immune disorders, such as albinism, psoriasis, nephrotic syndrome, systemic lupus erythematosus, and diabetes 5. Individuals with conditions like Tourette's syndrome or epilepsy.

Primary outcomes:
measure: Incidence of myopia
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tongren Hospital
Study officials:
affiliation: Beijing Tongren Hospital
name: Liya Qiao, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06296719: The Chit-Chat Educational Intervention to Promote Advance Care Planning in the Community
Official title: Empowering Family Members of Older Adults with Multi-morbidity in Advance Care Planning Conversations: Development and Feasibility Testing of the Chit-Chat Educational Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Old Age
Family Members
Keywords: Family members
Older Adults with multi-morbidity
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2024-03-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to estimate the effect size of the Chit-Chat intervention on ACP engagement among family members of older adults with multi-morbidity.

Detailed description: After being informed about the study and potential risks, all eligible participants will be asked to provide written informed consent for study entry. At week 0, participants will be randomized in an assessor-blinded randomized controlled trial in a 1:1 ratio to received the Chit-Chat intervention (two 2-hr weekly educational sessions) or wait-list control group.

Eligibility criteria: Inclusion Criteria:

* age 18 or above;
* a family member of a relative who aged 60 or above and lives with at least two severe chronic diseases such as cancer, dementia, lung, heart, liver, and renal disease.
* they perceived themselves will take part in taking care of their relatives in the near future;
* able to read and communicate in Cantonese.
* they are self-reported as cognitively intact

Exclusion Criteria:

* their relatives have been referred to palliative care service before the study.

Primary outcomes:
measure: ACP engagement
timeFrame: 2 Weeks; 1-month follow-up
Secondary outcomes:
measure: Knowledge of ACP
timeFrame: 2 Weeks; 1-month follow-up
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Hong Kong Polytechnic University
Study officials:
affiliation: The Hong Kong Polytechnic University
name: Doris YP Leung, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05232019: Association Between Embryo Implantation Rate and Maternal Age
Official title: Association Between Embryo Implantation Rate and Maternal Age in Different Embryo Transplantation Cycles: a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Lead sponsor: Nanjing University
Sponsor class: OTHER
First posted: 2022-02-09
Enrollment: 17394
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infertile females no less than 20 years old who were attending our clinical center for the first time were enlisted. In total, 17394 patients suffering from primary or secondary infertility were enrolled in this study.

Brief summary: To explore the relationship between maternal age and embryo implantation rate in patients undergoing assisted reproductive technology.

Detailed description: The investigators designed a retrospective clinical trial conducted from January 2015 to December 2020 at the Reproductive Medicine Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School. Infertility was defined as the failure of a clinical pregnancy after 12 months or more of regular unprotected intercourse with the same marriage partner. Patients experiencing infertility no younger than the age of 20 who attended the Reproductive Medicine Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School for the first time and had experienced no less than one embryo transplantation between January 2015 and December 2019 were recruited. Patients who had experienced or canceled embryo transplantation cycles for any reason were excluded from this study. The gap year from December 2019 to December 2020 allowed researchers to follow up on the outcomes of pregnancies before 2020. Frozen cycles were performed when high-quality embryos existed to avoid unnecessary ovarian stimulation and oocyte retrieval processes. Investigators were blinded to the outcome of embryo transplantation, and information on pregnancy was gathered through telephone follow-up one year after transplantation.

Eligibility criteria: Inclusion Criteria:

1. infertile patients
2. attended the Reproductive Medicine Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School for the first time
3. had experienced no less than one embryo transplantation between January 2015 and December 2019

Exclusion Criteria:

canceled embryo transplantation cycles for any reason

Primary outcomes:
measure: embryo implantation rate
timeFrame: 60 days after embryo transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School
state: Jiangsu
Study officials:
affiliation: The affiliated Drum Towel Hospital of Nanjing University Medical School
name: Haixiang Sun, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00697619: To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Official title: A Prospective, Open-label, Randomized Phase III Study to Evaluate the Efficacy of ZOMETA® (Zoledronic Acid) in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Nasopharyngeal Cancer
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
Collaborators: name: Novartis
First posted: 2008-06-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events) and to assess the safety in nasopharyngeal patients with bone metastases randomized to receive either zometa 4 mg or anti-neoplastic treatment alone.


Eligibility criteria: Inclusion Criteria:

* Age \>18, either sex
* Histologically confirmed stage IV nasopharyngeal cancer
* One bone metastasis at least confirmed by imaging
* without chemotherapy or radiotherapy after bone metastasis
* Life expectancy \> 6 M
* ECOG \<= 2
* Adequate bone marrow reserve (WBC \> 3.5 x 109/L, Neutrophile \> 1.5 x 109/L, Platelet 100 x 109/L, Hb \> 90 g/L)
* Serum creatinine\< 2.0 mg/dL (\< 1.5 times the upper limit of the normal range for the laboratory of the study center)
* Signed ICF

Exclusion Criteria:

* Women who are pregnant or in lactation
* Patients with hyperostosis
* Systemic treatment for another cancer within the year prior to study entry
* Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy
* Initial serum creatinine \>265 micromol/L and/or progressive renal disease
* Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures
* Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies
* Severe co-morbidity of any type that may interfere with assessment of the patient for the study

Primary outcomes:
measure: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms .
timeFrame: Baseline, the first, second and third month
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Li Zhang
state: Guangdong
Study officials:
affiliation: Cancer Center of Sun Yat-Sen University (CCSU)
name: Li Zhang, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02087319: Effect of PRP on the Therapy for Hair Growth
Official title: Application and Evaluation of PRP on the Therapy for Hair Loss Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hair Loss/Baldness
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2014-03-14
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of study is to examine the advantage of PRP on hair loss and male pattern baldness. The investigators will inject PRP into the scalp regions where with little or no hair, and evaluate the effect and efficiency of PRP on human hair growth.

Detailed description: Hair loss is a disorder in which the hair undergoes aberration growth cycles and falls out from scalp. A number of factors like hormones, genetic factors, diet, endocrine abnormalities, systemic illnesses, drug intake, and hair shaft abnormalities may cause hair loss. Androgen alopecia or male pattern baldness is the most common cause of hair loss caused by progressive shortening of the anagen and increased number of hair follicles in telogen, which has a significant influence on psychological distress.

Except medical treatment and baldness surgery, a new interest in treating hair loss and baldness has been stimulated by using platelet plasma growth factors obtained from the patient's own platelet-rich plasma (PRP). PRP is a portion of plasma fraction of autologous blood having a high concentration of thrombocytes, and can be activated by Thrombin to release multiple growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), and transforming growth factor beta (TGF-β). PRP is known for the capacity to stimulate cell proliferation and differentiation. The action of platelet plasma growth factors on the development of hair follicles has already been established. PRP has also been shown to increase the yield of implanted follicular units during male baldness surgery.

Our study will focus on the advantage of PRP for the treatment of hair loss and male pattern baldness. PRP from autologous blood can be mixed with thrombin in appropriate ratio and inject into the regions on scalp which is interested. We will track and evaluate regularly the effect and efficiency of PRP on human hair growth.

Eligibility criteria: Inclusion Criteria:

* patient with hair loss/baldness
* age of 20-70 years old

Exclusion Criteria:

* patient with systemic disorder
* phyco
* patient with coagulation abnormality
* patient with inflammation

Primary outcomes:
measure: examination the effect of PRP on hair loss/baldness
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
Study officials:
affiliation: organ transplantation center
name: Jeng Long-Bin
role: STUDY_CHAIR
References:
Clinical trial NCT01893619: Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome
Official title: Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Fatigue Syndrome
Keywords: Chronic fatigue syndrome
Karnofsky score
supplements
Lead sponsor: New York CFS Association
Sponsor class: OTHER
First posted: 2013-07-09
Enrollment: 100
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Fukuda criteria and Canadian consensus criteria will be the diagnosis criteria for patient selection

Brief summary: Observational study regarding the use of supplements in chronic fatigue syndrome patients

Detailed description: Detailed questionnaire regarding the diagnosis of an onset of chronic fatigue syndrome and 100 patients. using Karnofsky scale before and after use of supplements patient scores are compared in a double blind trial.

Eligibility criteria: Inclusion Criteria:

* Fukuda criteria and Canadian consensus criteria will be the diagnosis criteria for patient selection

Exclusion Criteria:

* non inclusion in the above criteria

Primary outcomes:
measure: Karnovsky score comparison
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Me/Cfs Center,860 Fifth Avenue
state: New York
Study officials:
affiliation: CFIDS RESEARCH FOUNDATION
name: DEREK enlander
role: PRINCIPAL_INVESTIGATOR
References: